Vallejos: Ivermectin to prevent hospitalizations in patients with COVID-19…

  • Vallejos: Ivermectin to prevent hospitalizations in patients with COVID-19…

  • CoS

    Member
    July 6, 2021 at 3:59 pm

    <b data-test=”article-title” data-article-title=””>Ivermectin
    to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19)
    a randomized, double-blind, placebo-controlled trial

    https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06348-5

    Unlike the Columbia study, none of the participants in this study disclosed any conflict of interest.

    However, like the Columbia study, this trial also reported fewer cases of severe symptoms, less that predicted.

    And like the Columbia study, they assigned people with a history of taking ivermectin into the placebo arm, excluding only those who reported taking ivermectin within the prior 7 days. The Columbia trial allowed those who used ivermectin less than 5 days prior into the placebo arm. Both trials should therefore be seen as being potentially an ivermectin vs ivermectin comparison.

    This trial used 2 doses at the level recommended for parasitic infection. There was no mention of whether or not it was taken with/after a meal (preferred for covid) or on an empty stomach as recommended for parasites. The difference is critical as when taken with a meal containing fats, 2-3 times more ivermectin is absorbed.

    Experts at treating Covid-19 at FLCCC consider 2 doses of ivermectin appropriate for prophylaxis but recommend higher and continued daily doses for those who have contracted Covid. https://covid19criticalcare.com/covid-19-protocols/i-mask-plus-protocol/

    Ivermectin’s anti-viral properties are useful during the virus replication stage, which seems to be the first 5-7 days after infection. Giving ivermectin towards the end of this stage or after negates it’s anti-viral benefits. Treating at first symptom is critical for best results. Trials like this which delay intervention for days after first symptom will show a lesser benefit as for viral clearance. after that, ivermectin’s anti-inflammatory characteristics enter the picture but a trial must include markers for that to show related effects.

    A trial doing too little too late is not helpful in documenting best practice. Notating the outcomes in relation to how soon a therapeutic was given from first symptom would be more informing.

    These observations come from a quick reading of the study. A more thorough review by more competent persons will reveal additional concerns and weaknesses I assume.

    <b data-test=”abstract-sub-heading”>Results

    The mean age was 42 years (SD ± 15.5) and the median time since symptom onset to the inclusion was 4 days [interquartile range 3–6]. The primary outcome of hospitalization was met in 14/250 (5.6%) individuals in ivermectin group and 21/251 (8.4%) in placebo group (odds ratio 0.65; 95% confidence interval, 0.32–1.31; p = 0.227). Time to hospitalization was not statistically different between groups. The mean time from study enrollment to invasive mechanical ventilatory support (MVS) was 5.25 days (SD ± 1.71) in ivermectin group and 10 days (SD ± 2) in placebo group, (p = 0.019). There were no statistically significant differences in the other secondary outcomes including polymerase chain reaction test negativity and safety outcomes.

  • CoS

    Member
    July 6, 2021 at 4:38 pm

    Moderator – please delete this as a far better analysis has since been posted by the TrialSite team

Viewing 1 - 2 of 2 replies

Original Post
0 of 0 posts June 2018
Now